SCYNEXIS, Inc.
$4.46
$0.01 (+0.22%)
$4.41Day Range$4.70
Key Statistics
Market Cap
$44.28M
Shares Outstanding
9.9M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
May 2, 2014
Round Lot
100
Locale
US
Trading Data
Day Open
$4.49
Day High
$4.70
Day Low
$4.41
Volume
68.8K
VWAP
$4.53
Prev Close
$4.45
Transactions
--
Acc. Volume
--
About SCYNEXIS, Inc.
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.
PHARMACEUTICAL PREPARATIONSSIC 283429 employees1 EVERTRUST PLAZA, JERSEY CITY, NJ, 07302-6548201-884-5485IPO May 2, 2014US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001178253
- Composite FIGI
- BBG002133YW4
- Share Class FIGI
- BBG002133YY2
- Ticker Root
- SCYX
- SIC Code
- 2834
About SCYNEXIS, Inc. (SCYX) Stock
SCYNEXIS, Inc. (SCYX) closed the 2026-09-18 session at $4.46, up 0.22% versus the previous close (+0.01). The stock opened at $4.49 and traded between $4.41 and $4.70 during that session. Session trading volume was 69K shares. The volume-weighted average price (VWAP) is $4.53.
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.
SCYNEXIS, Inc. has a market capitalization of $44.3 million. The company operates in the PHARMACEUTICAL PREPARATIONS industry classification. SCYX is listed on the XNAS exchange. The company employs approximately 29 people. SCYNEXIS, Inc. is headquartered in JERSEY CITY, NJ. The recorded listing date is 2014-05-02.
On this page you can find market SCYX stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the PHARMACEUTICAL PREPARATIONS sector.